Kanuma market outlook points to growth in rare disease treatment

The Business Research Company says the Kanuma market is set to expand through 2035 as newborn screening, rare disease awareness and enzyme technology improve diagnosis and treatment of lysosomal acid lipase deficiency. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Kanuma treats lysosomal acid lipase deficiency, a rare genetic disorder that can cause liver damage and cardiovascular complications. - Growth in diagnosis and treatment access could expand demand for enzyme replacement therapy and improve outcomes for patients who are found earlier. - The market outlook matters for rare disease drug makers because LAL-D has historically been underdiagnosed and under-treated.

What happened: - The Business Research Company published its Kanuma Global Market Report 2026 – Market Size, Trends, and Forecast 2026-2035 on Nov. 5, 2026. - The report says the Kanuma market grew steadily in recent years despite limited treatment options, low awareness of LAL-D, and care concentrated in specialist centers. - The company said the market is expected to expand on the back of broader newborn screening, more awareness of rare diseases, improved access to specialized care, and more funding for orphan drug therapies. - Download a free sample of the report. - View the full market report.

The details: - Kanuma, or sebelipase alfa, is a recombinant enzyme replacement therapy for lysosomal acid lipase deficiency. - LAL-D causes lipids to build up in tissues and can lead to liver disease, metabolic problems, and cardiovascular issues. - Kanuma works by replacing the missing enzyme so the body can break down harmful lipid deposits. - The report identifies rising LAL-D prevalence as a key growth driver. - Improved diagnostic technology and greater disease awareness are leading to more diagnosed cases. - The report cites a March 2023 National Institutes of Health estimate that LAL-D prevalence ranges from about 1 in 40,000 to 1 in 300,000 people, depending on ethnicity and region. - Rising healthcare spending is also supporting market growth. - A UK government report from May 2024 found total healthcare spending rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% the prior year. - The same UK report said long-term health and social care spending grew 2.8% in real terms in 2022. - In 2025, North America held the largest share of the Kanuma market. - The Asia-Pacific region is projected to be the fastest-growing market during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics, and key technology and future trend analysis.

Between the lines: - The report points to a familiar rare-disease pattern: better screening and awareness can expand the addressable market even when the underlying patient population remains small. - The emphasis on pediatric rare disease treatment and earlier diagnosis suggests growth may come more from earlier intervention than from a large jump in total patient counts. - The healthcare spending data reinforces that reimbursement and system capacity will remain important for high-cost orphan drugs.

What's next: - The market’s near-term path will likely depend on how quickly newborn screening expands and how consistently health systems identify LAL-D patients earlier. - Continued investment in recombinant enzyme technology and orphan drug funding could shape future treatment adoption. - Regional growth should be strongest where access to specialty care is improving fastest, especially in Asia-Pacific.

The bottom line: - Kanuma’s market outlook is tied to a slow but meaningful shift: better detection, better access and a growing rare-disease treatment infrastructure are supporting long-term demand.